KineMed Licenses GeneGo Software for Leukemia Study | GenomeWeb
NEW YORK (GenomeWeb News) – KineMed has licensed GeneGo’s MetaCore software for an ongoing Phase II prognostic study of chronic lymphocytic leukemia, GeneGo said today.
 
KineMed is testing a biomarker of CLL flux as a predictor of disease course that is intended to stratify indolent versus aggressive disease.
 
MetaCore is GeneGo’s flagship product and is used for target selection and validation, identification of biomarkers for disease states, and toxicology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.